Epidemiological changes in hepatitis B prevalence in an entire population after 20 years of the universal HBV vaccination programme

Epidemiology and Infection

Volumn 139, Issue 8, 2011, Pages 1159-1165

  Shen, L P ^a   Zhang, Y ^a   Wang, F ^a   Zhang, S ^a   Yang, J Y ^b   Fang, K X ^c   Yu, T ^a   Wang, X Y ^a   Zhang, W Y ^a   Bi, S L ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention   (China)

^c Center for Disease Control and Prevention of Long An County   (China)

Author keywords

Epidemiological distribution; HBV infection; hepatitis B; universal vaccination

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RADIOIMMUNOASSAY; SCHOOL CHILD; SEROPREVALENCE; SEX DIFFERENCE; VACCINATION; BLOOD; CHINA; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHINA; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS C ANTIBODIES; HUMANS; INFANT; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 80052159071     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268810002827     Document Type: Article

References (28)

1. Xia GL, Liu CB, Cao HL. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemologic study of hepatitis A, B, C, D, and E virus infections in China, 1992. International Hepatology Communications 1996; 5: 62-73.
2. Liang X, et al. Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-6557.
3. Goldstein ST, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005; 34: 1329-1339. (Pubitemid 41819540)
4. Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. New England Journal of Medicine 2004; 351: 2832-2838. (Pubitemid 40051907)
5. Namgyal P. Impact of hepatitis B immunization, Europe and worldwide. Journal of Hepatology 2003; 39 (Suppl. 1): S77-82. (Pubitemid 37222651)
6. Viviani S, et al. Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine 1999; 17: 2946-2950. (Pubitemid 29366973)
7. Hsu HM, et al. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immunization. Journal of Infectious Diseases 1999; 179: 367-370.
8. Whittle H, et al. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. British Medical Journal 2002; 325: 569.
9. Chang MH, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. New England Journal of Medicine 1997; 336: 1855-1859.
10. Chang MH, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. Journal of the National Cancer Institute 2009; 101: 1348-1355.
11. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 2008; 26: 6266-6273.
12. Viviani S, et al. 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Search Results Cancer Epidemiology, Biomarkers & Prevention 2008; 17: 3216-3223.
13. CDC. Progress in hepatitis B prevention through universal infant vaccination-China, 1997-2006. Morbidity and Mortality Weekly Report 2007;56:441-445.
14. Xu ZY, et al. Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-Peoples Republic of China Study Group on Hepatitis B. Journal of Infectious Diseases 1995; 171: 54-60.
15. Li H, et al. Comprehensive evaluation of an infant hepatitis B immunization strategy of Longan county of China. Journal of Chinese Medical Sciences 1999; 14: 21-25.
16. Beasley RP, et al. Evidence against breast-feeding as a mechanism for vertical transmission of hepatitis B. Lancet 1975; 2: 740-741.
17. Mast EE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. Morbidity and Mortality Weekly Report. Recommendations and Reports 2005; 54: 1-31.
18. Liao SS, et al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661-2666.
19. Ding ZR, et al. Distribution of hepatitis B infection markers in Guangxi province. Gan Yan Fang Zi Yan Jiu 1985; 1: 10-21.
20. Li H, et al. Long-term effectiveness of infancy low-dose hepatitis B vaccine immunization in Zhuang minority area in China. World Journal of Gastroenterology 1999; 5: 122-124.
21. Gong J, et al. Long-term efficacy of infant hepatitis B immunization program [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2003; 11: 203-205.
22. Li H, et al. Research on optimal immunization strategies for hepatitis B in different endemic areas in China. World Journal of Gastroenterology 2000; 6: 392-394. (Pubitemid 30392137)
23. Jack AD, et al. What level of hepatitis B antibody is protective ? Journal of Infectious Diseases 1999; 179: 489-492. (Pubitemid 29086654)
24. Szmuness W. Recent advances in the study of the epidemiology of hepatitis B. American Journal of Pathology 1975; 81: 629-650.
25. Blumberg BS, et al. Sex distribution of Australia antigen. Archives of Internal Medicine 1972; 130: 227-231.
26. Wang SH, et al. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology 2009; 50: 1392-1402.
27. Creati M, et al. Implementing the birth dose of hepatitis B vaccine in rural Indonesia. Vaccine 2007; 25: 5985-5993. (Pubitemid 47077548)
28. Marion SA, et al. Long-term follow-up of hepatitis B vaccine in infants of carrier mothers. American Journal of Epidemiology 1994; 140: 734-746. (Pubitemid 24322186)